Standout Papers

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance 2019 2026 2021 2023 1.5k
  1. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance (2019)
    Filipe Martins, Sofiya Latifyan et al. Nature Reviews Clinical Oncology

Immediate Impact

6 by Nobel laureates 28 from Science/Nature 57 standout
Sub-graph 1 of 22

Citing Papers

The B7:CD28 family and friends: Unraveling coinhibitory interactions
2024 Standout
Rheumatoid arthritis: pathogenesis and therapeutic advances
2024 Standout

Works of François Spertini being referenced

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease
2018

Author Peers

Author Last Decade Papers Cites
François Spertini 2364 868 1319 1664 200 6.6k
Peter Fritsch 4029 857 2060 1523 245 9.7k
Max Schlaak 1513 1262 1364 1732 271 7.3k
Roger D. Rossen 2173 495 1511 514 147 6.6k
Jacques Bienvenu 3794 659 1370 964 201 8.5k
Yoshiaki Ishigatsubo 2139 401 2141 1133 408 8.4k
Seymour Katz 4041 1046 1281 926 244 10.8k
Stig S. Frøland 4551 540 2189 1195 224 11.3k
Alan D. Schreiber 2902 699 2670 685 138 8.3k
John Freedman 2269 595 1024 548 222 9.2k
Christian Grønhøj 1854 722 893 1190 114 5.1k

All Works

Loading papers...

Rankless by CCL
2026